Life Sciences
Life sciences companies are under pressure to deliver more innovation for less. We help them do it.
Pharmaceutical, biotechnology and medical technology companies face pricing pressure, patent expiries, complex supply chains and the promise of AI to transform research, development and commercialization.
Solving your complex challenges
Allocating capital effectively to generate growth and improve returns
Portfolio and capital allocation strategy for life sciences.
ExploreImproving operational efficiency to fund growth
Cost and productivity programs across R&D, manufacturing and commercial.
Configuring adaptive manufacturing and supply chains
Why asset-light models matter now.
ExploreUsing data to deliver innovation to patients faster
Data platforms that link treatments to outcomes.
ExploreExplore Life Sciences solutions
How biopharma can get the right mix of people and technology for launch success
Biopharma companies need an end-to-end, AI-enabled launch strategy to succeed in a challenging market.
How life sciences legal teams prepare for a technology-driven future
Emerging health technology creates new data flows and new legal and privacy questions for life sciences companies.
How next-generation CRM will reshape the life sciences commercial model
Customer relationship management in life sciences must move from static maps to real-time navigation.
What pharma supply chain transformation means for tax
Companies building resilient supply chains should involve tax and transfer pricing teams early.
Why biopharma needs asset-light manufacturing models now
Biopharma manufacturing is moving from building to partnering. Asset-light models and AI cut costs and increase agility.
Why licensing deals are a powerful source of growth in life sciences
Pharmaceutical companies increasingly use licensing to access external innovation and grow with lower risk.
Naizel Partner Ecosystem
We work with life sciences software, data and AI partners to accelerate commercial and R&D transformation. Learn more.
The team
Daniel Matthews
Global Life Sciences Leader
Related insights
How biopharma can get the right mix of people and technology for launch success
Biopharma companies need an end-to-end, AI-enabled launch strategy to succeed in a challenging market.
How life sciences legal teams prepare for a technology-driven future
Emerging health technology creates new data flows and new legal and privacy questions for life sciences companies.
How next-generation CRM will reshape the life sciences commercial model
Customer relationship management in life sciences must move from static maps to real-time navigation.
What pharma supply chain transformation means for tax
Companies building resilient supply chains should involve tax and transfer pricing teams early.
Why biopharma needs asset-light manufacturing models now
Biopharma manufacturing is moving from building to partnering. Asset-light models and AI cut costs and increase agility.
Why licensing deals are a powerful source of growth in life sciences
Pharmaceutical companies increasingly use licensing to access external innovation and grow with lower risk.